iRhythm Technologies (IRTC) Stock Forecast & Price Target

iRhythm Holdings is supported by a durable core growth engine, with Q3 revenue of $221.6M rising 14.9% year over year as Zio Monitor outperformed across cardiology, primary care, innovative channels, and international markets. Even with Zio AT temporarily flat and the Zio MCT filing pushed into 2027, the company still showed powerful operating leverage through a 74.2% gross margin and a record 23.1% adjusted EBITDA margin, while FY26 revenue guidance rose to $890M-$895M and EBITDA margin to 15.5%-16.0%. The VitalConnect deal also broadens its MCT reach and should help de-risk the longer-term product mix, giving the company a clearer path to sustained 15%+ organic growth and margin expansion.

iRhythm Holdings is facing a weakening fundamental backdrop as reimbursement pressure, tighter prior authorization, and commercial payor scrutiny threaten revenue quality and could drive lower realized pricing across its diagnostic testing business. Operationally, the delayed Zio MCT filing into 2027, the pause in Zio AT onboarding, and flat y/y Zio AT revenue signal execution risk and potential channel cannibalization just as management works to integrate VitalConnect and restore product momentum. At the same time, the June 2023 FDA warning letter and persistent 2024 compliance observations raise regulatory overhangs, while rising competition and slower-than-expected expansion into new markets may limit growth even if FY27 organic revenue trends toward $1B with gross margin above 70% and adjusted EBITDA margin of at least 15%.